(P-2026) Obeldesivir for the Treatment of COVID-19 in People with Risk Factors for Progression to Severe Disease: the BIRCH Study

Chef of Infectious Diseases Unit 5 at Matei Bals National Infectious Diseases Institute
"Prof. Dr. Matei Bals" National Institute for Infectious Diseases Carol Davila Medicine and Pharmacy University
Bucharest, Bucuresti, Romania

Investigator
IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University
Milano, Lombardia, Italy

Professor
National Taiwan University Hospital
Taipei, Taipei, Taiwan (Republic of China)

Investigator
Kaohsiung Veterans General Hospital
Kaohsiung, Kaohsiung

Gilead Sciences, Inc.
Foster City, California, United States

Gilead Sciences, Inc.
Foster City, California, United States

Gilead Sciences, Inc.
Foster City, California, United States

Gilead Sciences, Inc.
Foster City, California, United States

Gilead Sciences, Inc.
Foster City, California, United States

Gilead Sciences, Inc.
Foster City, California, United States

Senior Research Scientist
Gilead Sciences, Inc.
Foster City, California, United States

Director
Gilead Sciences, Inc
Foster City, California, United States

Gilead Sciences, Inc.
Foster City, California, United States

Gilead Sciences Europe Ltd
Uxbridge, England, United Kingdom

Clinical Development
Gilead Sciences, Inc.
Foster City, California, United States

Clinical Research
Gilead
Foster City, California, United States

Senior Vice President
Gilead Sciences, Inc
San Francisco, California, United States

FAICIC Clinical Research
Veracruz, Veracruz-Llave, Mexico

Ormeau Clinical Trials
Belfast, Northern Ireland, United Kingdom

DIRECTOR
Köhler & Milstein Research/Hospital Agustín O’Horán
Mérida, Yucatan, Mexico

Brazilian National Cancer Institute; Faculdade de Medicina da Universidade Municipal de Sao Caetano do Sul
Rio de Janeiro; São Paulo, Rio de Janeiro, Brazil

Limpopo Clinical Research Initiative
Thabazimbi, Limpopo, South Africa

Emergency Department, Hospital Clínico Universitario San Carlos
Madrid, Madrid, Spain